Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

Chest

Volumn 136, Issue 5, 2009, Pages 1211-1219

  Hachulla, Eric ^a,b   Launay, David ^a,b   Mouthon, Luc ^c,d   Sitbon, Olivier ^e,f   Berezne, Alice ^c,d   Guillevin, Loïc ^c,d   Hatron, Pierre Yves ^a,b   Simonneau, Gérald ^e,f   Clerson, Pierre ^g   Humbert, Marc ^e,f  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Assistance Publique Hôpitaux de Paris ^*  (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g Orgamètrie biostatistiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

EID: 70449369308     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-3042     Document Type: Article

References (25)

1. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1093 (Pubitemid 37323574)
2. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792-3800 (Pubitemid 41798217)
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944
4. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54:3043-3050 (Pubitemid 44497786)
5. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(suppl):5S-12S
6. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29:255-273
7. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma): subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205 (Pubitemid 18073738)
9. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14:270-274 (Pubitemid 29461288)
10. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158:1384-1387 (Pubitemid 28536595)
11. Coral-Alvarado P, Rojas-Villarraga A, Latorre MC, et al. Risk factors associated with pulmonary arterial hypertension; in Colombian patients with systematic sclerosis: review of the literature. J Rheumatol 2008; 35:244-250 (Pubitemid 351281145)
12. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35:458-465
13. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453-459 (Pubitemid 32409560)
14. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966:238-246 (Pubitemid 34729180)
15. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33:269-274 (Pubitemid 43209302)
16. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis. demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81:139-153 (Pubitemid 34218569)
17. Simeon CP, Armadans L, Fonollosa R, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42:71-75 (Pubitemid 36131570)
18. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35:765-770
19. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220-233
20. Dorfmüller P, Humbert M, Perros F, et al. Fibrous remodelling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38:893-902 (Pubitemid 46735956)
21. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516-522 (Pubitemid 36278021)
22. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350 (Pubitemid 36269414)
23. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926-932 (Pubitemid 43974055)
24. British Cardiac Society. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86:i1-i13 (Pubitemid 32800062)
25. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371:2093-2100 (Pubitemid 351902178)